Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1077277 | 0.87 | SIGMAR1 (0.33) | GNAI3GNAO1GNAI1SIGMAR1CHRM5 | |
| SCHEMBL7678677 | 0.81 | SIGMAR1 (0.37) | SIGMAR1CHRM5CHRM3 | |
| SCHEMBL9990034 | 0.80 | SIGMAR1 (0.36) | GNAI3GNAO1GNAI1SIGMAR1CHRM5 | |
| SCHEMBL665673 | 0.76 | SIGMAR1 (0.36) | GNAI3GNAO1GNAI1SIGMAR1CHRM5 | |
| SCHEMBL9990046 | 0.74 | SIGMAR1 (0.33) | GNAI3GNAO1GNAI1SIGMAR1CHRM5 | |
| SCHEMBL2764635 | 0.74 | SIGMAR1 (0.33) | GNAI3GNAO1GNAI1SIGMAR1CHRM5 | |
| SCHEMBL4789533 | 0.74 | L3MBTL1 (0.40) | KMT2A | |
| SCHEMBL9533096 | 0.73 | SIGMAR1 (0.32) | GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL1408779 | 0.72 | GNAI3 (0.33) | GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL1088468 | 0.72 | SIGMAR1 (0.37) | SIGMAR1CHRM5CHRM3LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3801522-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-7501407-B2 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-6916804-B2 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | GNAI3 2478/4885GNAO1 418/4885GNAI1 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.